<DOC>
	<DOCNO>NCT01857921</DOCNO>
	<brief_summary>Trimetazidine metabolic agent without negative inotropic vasodilatory property . In addition , previous report show trimetazidine effective reduce intracoronary platelet aggregation prevent platelet thrombogenesis . Therefore , evaluation combination effect statin trimetazidine patient aspirin monotherapy previously receive CABG free major adverse cardiac event death , MI , TLR , TVR 12 month , investigator hypothesize atorvastatin 40mg/day would effective prevention late adverse cardiac cerebrovascular event statin . To test hypothesis , investigator perform multi-center , randomize , prospective trial aim demonstrate superiority combination high dose atorvastatin therapy trimetazidine pravastatin patient aspirin monotherapy 12 month CABG surgery real world practice .</brief_summary>
	<brief_title>Combination Effects High-dose Statin Trimetazidine Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass Surgery</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Trimetazidine</mesh_term>
	<criteria>Patients previously receive CABG 12 month ago Patients free death , MI repeat revascularization within first 12 month CABG Patients mono antiplatelet therapy aspirin alone Age 20 year old Patients sign informed consent History DES BMS implantation within 12 month Patients require continue dual antiplatelet therapy additional type antithrombotics antiplatelets cilostazol ticlopidine , etc besides aspirin DES implantation Patients could prescribe aspirin statin due contraindication severe side effect Pregnant woman woman potential childbearing Life expectancy â‰¤ 2 year</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>